In the United States, two drugs have been approved to treat female sexual interest/arousal disorder (FSIAD): Vyleesi (bremelanotide) and Addyi (flibanserin). Some people may refer to these as “V ...
Whether the “little pink pill” is a boon or a boondoggle depends on who you ask Flibanserin, soon to be marketed as Addyi, has been in clinical trials to treat low desire since the mid-2000s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results